Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rivian Automotive, Inc. (RIVN) vs Twist Bioscience Corp (TWST) Price & Performance

Rivian Automotive, Inc.Trade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Rivian Automotive, Inc. vs Twist Bioscience Corp — how do they compare? Rivian Automotive, Inc. trades at $14.21 (market cap $20.75B), while Twist Bioscience Corp trades at $159.84 (market cap $10.08B). The key difference: Rivian Automotive, Inc. is far larger — about 2.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Twist Bioscience Corp for 27 Days on average.

RIVNTWST
Market Cap
$20.75B$10.08B
Volume
26,144,6544,229,037
Sector
Consumer CyclicalHealth
52-Week High
$22.45$205.00
52-Week Low
$12.50$25.45
Typical Hold Time
61 Days27 Days
Enterprise Value
$20.79B$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $14.34, down 1.17% amid bearish technical signals despite strong Q3 2026 delivery growth of 46% to 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving cash flow trends with operating losses narrowing from -$5.1B in 2022 to -$779M in 2025. Recent news highlights R2 SUV production ramp and autonomy technology development, though the stock faces pressure from unchanged 2026 guidance and a recent R2 battery pack recall.

Rivian presents a high-risk growth opportunity with significant cash burn but improving operational efficiency. The path to profitability depends on successful R2 scaling and future autonomy revenue, while near-term risks include execution challenges and competitive EV market pressures. Analyst consensus remains cautiously optimistic with a $16.89 price target representing 18% upside potential.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.

The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RIVN

No sentiment data available yet.

TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →